AI Enhanced Therapeutic Antibody Development
Precision Antibodies. Life-Changing Outcomes.
IMGENEX INDIA is a pioneering biotechnology company committed to advancing human health through cutting-edge therapeutic research and contract development services. Founded on the principle that innovative solutions must also be affordable, we bridge the gap between groundbreaking science and real-world clinical application. The R&D unit of IMGENEX India was inaugurated in 2005 by Dr. APJ Abdul Kalam, the then Hon'ble President of India.
The company's integrated platform includes antigen design, recombinant protein production, monoclonal antibody development, stable cell line generation, mammalian and bacterial expression systems, and advanced drug discovery screening assays. These capabilities enable the design, expression, optimization, and validation of recombinant antibody formats such as scFvs, bispecific antibodies, and next-generation antibody therapeutics. Through its focus on antibody discovery, biosimilar development, protein engineering, and translational research, IMGENEX India is advancing innovative antibody technologies aimed at affordable healthcare solutions and precision medicine applications.